53
Participants
Start Date
May 31, 2007
Primary Completion Date
June 30, 2009
Study Completion Date
October 31, 2009
Blinded (placebo)
"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
Open Label (Avatrombopag tablets)
"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
Blinded (Avatrombopoag tablets)
"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
Mount Sinai Medical Center, New York
New York Presbyterian Hospital, Weill Medical College of Cornell University, New York
Emerywood Oncology and Hematology, High Point
Florida Cancer Institute, New Port Richey
Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center, Columbus
Cancer Care Center, Inc., New Albany
John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology, Chicago
Kansas City Cancer Center, LLC, Kansas City
Capitol Comprehensive Cancer Care Clinic, Jefferson City
Pacific Cancer Medical Center, Inc, Anaheim
Comprehensive Blood and Cancer Center, Bakersfield
Davis, Posteraro and Wasser, MDs, LLP, Manchester
Eisai Inc.
INDUSTRY